Solriamfetol: A Potential Game-Changer for Adult ADHD Treatment

Possible Narcolepsy Medication as Alternative Treatment for ADHD

Narcolepsy drug shows promise for treating ADHD

Narcolepsy Drug Might Be New Treatment Option for ADHD

Attention-deficit/hyperactivity disorder (ADHD) can be quite a challenge for adults who are desperately seeking relief from their symptoms. But fear not! A small pilot study has shown that solriamfetol, a medication originally approved for excessive daytime sleepiness, may offer a glimmer of hope for these adults.

Solriamfetol, a nonstimulant drug designed to combat sleepiness caused by narcolepsy and sleep apnea, has stepped into the spotlight as a potential treatment for adult ADHD. Dr. Craig Surman, the study’s author, expressed cautious optimism about the drug’s potential, saying, “The pilot study is very promising, but more research is needed before this medication can be recommended or approved for adults with ADHD.”

In the study, 60 adults with ADHD were divided into two groups: one that took solriamfetol and another that took a placebo. They diligently recorded their symptoms and experiences over the course of a six-week period. The results were clear: those taking solriamfetol reported more improvements in their ADHD symptoms compared to those who took the placebo.

This groundbreaking study was funded by Jazz Pharmaceuticals and Axsome Therapeutics, the makers of solriamfetol. Currently, ADHD in adults is primarily treated with a combination of medication and behavioral therapy. Stimulant drugs like Adderall and Ritalin are commonly prescribed, but not everyone can tolerate these medications. Therefore, the potential addition of solriamfetol to the treatment options for adults with ADHD is an exciting development.

So how does solriamfetol work its magic? The drug increases dopamine and norepinephrine, which are neurotransmitters that play crucial roles in regulating sleep and wakefulness. These brain chemicals are also targeted by existing ADHD medications.

But what about side effects, you ask? Well, mild side effects such as decreased appetite, headaches, insomnia, and stomach discomfort were reported, but they were not severe enough for participants to discontinue using the drug. Plus, solriamfetol does not affect heart rate or blood pressure, which is particularly important since ADHD medications are often taken for extended periods.

Adult ADHD often flies under the radar compared to its pediatric counterpart. However, it can have a significant impact on health and quality of life. Dr. Surman highlighted the challenges faced by adults with untreated ADHD, stating, “Adults with untreated ADHD lead last-minute, reactive lives that can impact what time they get to bed or what they eat during a busy week, all of which can affect their health.”

The treatment of adult ADHD combines “pills and skills.” Medication and behavioral interventions work hand in hand to provide symptom relief and improve day-to-day functioning. According to Dr. Deepti Anbarasan, a clinical associate professor of psychiatry and neurology, solriamfetol’s mechanism of action aligns with medications used in ADHD, making it a potential game-changer.

While further research is still needed to solidify solriamfetol’s position as a treatment option for adult ADHD, the possibility of having a nonstimulant medication that is comparable to stimulants is truly exciting. Moreover, nonstimulant medications come with fewer regulations and supply limitations compared to their stimulant counterparts.

In conclusion, solriamfetol represents a promising development in the field of adult ADHD treatment. More research is required to fully understand its potential, but the initial findings are undoubtedly encouraging. As always, stay informed and consult with your healthcare provider to find the best treatment approach for your specific needs.

Stay focused, stay informed, and let’s tackle adult ADHD together!


Readers, we want to hear from you! Are you excited about the potential of solriamfetol for adult ADHD treatment? Share your thoughts and experiences in the comments below!


Sources:

Image Source: